Humana (NYSE:HUM) Price Target Raised to $312.00 at Bank of America

Humana (NYSE:HUM) had its price objective upped by Bank of America from $285.00 to $312.00 in a research report released on Tuesday,Benzinga reports. Bank of America currently has a neutral rating on the insurance provider’s stock.

A number of other research firms have also weighed in on HUM. Royal Bank Of Canada raised their price objective on shares of Humana from $283.00 to $322.00 and gave the company an “outperform” rating in a research note on Thursday, August 21st. Wells Fargo & Company reduced their price target on shares of Humana from $348.00 to $344.00 and set an “overweight” rating for the company in a research note on Thursday, August 14th. Morgan Stanley reduced their price target on shares of Humana from $290.00 to $277.00 and set an “equal weight” rating for the company in a research note on Thursday, July 31st. Truist Financial reduced their price target on shares of Humana from $280.00 to $260.00 and set a “hold” rating for the company in a research note on Wednesday, July 16th. Finally, Wall Street Zen lowered shares of Humana from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Seven equities research analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $285.76.

Humana Stock Up 2.1%

NYSE:HUM opened at $310.05 on Tuesday. The firm has a market cap of $37.29 billion, a P/E ratio of 23.80, a P/E/G ratio of 1.79 and a beta of 0.44. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. Humana has a fifty-two week low of $206.87 and a fifty-two week high of $382.72. The firm has a 50-day simple moving average of $257.24 and a two-hundred day simple moving average of $255.32.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). The firm had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. Analysts predict that Humana will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.1%. Humana’s dividend payout ratio (DPR) is presently 27.17%.

Hedge Funds Weigh In On Humana

A number of institutional investors and hedge funds have recently made changes to their positions in HUM. Norges Bank purchased a new position in shares of Humana in the second quarter worth approximately $397,079,000. Vanguard Group Inc. boosted its holdings in shares of Humana by 8.9% in the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock worth $3,697,222,000 after buying an additional 1,143,662 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Humana by 3,257.5% in the first quarter. AQR Capital Management LLC now owns 1,162,600 shares of the insurance provider’s stock worth $307,624,000 after buying an additional 1,127,973 shares during the last quarter. Leith Wheeler Investment Counsel Ltd. boosted its holdings in shares of Humana by 661.7% in the second quarter. Leith Wheeler Investment Counsel Ltd. now owns 1,038,703 shares of the insurance provider’s stock worth $253,942,000 after buying an additional 902,340 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Humana by 40,881.1% during the first quarter. GAMMA Investing LLC now owns 781,099 shares of the insurance provider’s stock valued at $2,066,790,000 after purchasing an additional 779,193 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.